Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA7 | P43166 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401414 | 0.84 | NOTUM (0.64) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1868624 | 0.84 | NOTUM (0.64) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13290826 | 0.83 | CA12 (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13807307 | 0.82 | NOTUM (0.45) | CA1CA2CA7CA9NOTUM | |
| SCHEMBL4757744 | 0.82 | MEN1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL288382 | 0.82 | BRD4 (0.53) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31135164 | 0.82 | MEN1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL22092817 | 0.82 | CA12 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10180584 | 0.81 | CA12 (0.64) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2712707 | 0.81 | CA12 (0.64) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113412113-B | Amino oxazinamides | 豪夫迈·罗氏有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20210363152-A1 | AMINOAZINE AMIDES | HOFFMANN LA ROCHE (US) | 2021-11-25 | — | — | US | disclosed |
| CN-113412113-A | Aminooxazine amides | 豪夫迈·罗氏有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3873473-A1 | AMINOAZINE AMIDES | F. Hoffmann-La Roche AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| WO-2020123426-A1 | AMINOAZINE AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119896-A1 | HETEROCYCLIC INHIBITORS OF ATX | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | CA1 3416/4885CA2 912/4885CA7 860/4885 |
| US-20210363152-A1 | AMINOAZINE AMIDES | SLC6A15, SLC1A5, SLC7A5 | CA1 1306/4885CA2 660/4885CA7 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.